Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.
Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.
复制标题
DOI：
10.15420/cfr.2019.19
复制
发表时间：
2020-03
影响因子：
--
通讯作者：
Lurz P
中科院分区：
文献类型：
--
作者：
Rosch S;Rommel KP;Scholz M;Thiele H;Lurz P
与射血分数降低的心力衰竭相比，保留射血分数的心力衰竭（HFpEF）的发病率正在增加，患病率更高。迄今为止，由于其复杂的潜在病理生理和临床异质性，尚无有效的治疗方法。本文旨在对HFpEF的转录组生物标志物研究进行综述和展望。HFpEF表型及其潜在分子病理机制的详细描述可能为早期诊断、改善预后、新的治疗靶点和针对患者异质性的量身定制治疗开辟新的视角，从而可能提高生活质量。横截面和纵向研究设计的结合需要足够大的样本量来支持这一概念。
Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.